FDA Updates iPLEDGE Rules for Isotretinoin Acne Treatment
What the iPLEDGE changes mean for people taking isotretinoin
Getting isotretinoin for severe acne involves more steps than filling many other prescriptions. That’s because the medication can cause severe birth defects if a pregnancy occurs during treatment.
Changes to the iPLEDGE safety program took effect on November 15, 2026. According to the U.S. Food and Drug Administration (FDA), the updates are intended to make some requirements easier for patients, prescribers, and pharmacies while keeping safeguards in place to reduce the risk of fetal exposure. (Source: FDA, iPLEDGE Risk Evaluation and Mitigation Strategy)
Isotretinoin is approved for people ages 12 and older who have severe nodular acne, a type of acne that causes deep lumps under the skin, and whose acne has not responded to other treatments. It is not approved for use during pregnancy. (Source: FDA, Isotretinoin Capsule Information)
Why iPLEDGE still matters
Anyone prescribed isotretinoin must continue to participate in iPLEDGE. It is a Risk Evaluation and Mitigation Strategy (REMS), a medication safety program required by the FDA to help manage serious risks.
The updated rules change how some parts of the program work, but pregnancy-related safeguards remain central to it. Treatment decisions and questions about individual requirements should be discussed with a doctor or dermatologist.
More options for pregnancy testing
People who can become pregnant must still complete the required pregnancy tests in a medical setting before starting isotretinoin.
After treatment begins, prescribers may allow monthly pregnancy tests to be done outside a medical setting, including at home. This option may also apply to testing after treatment. If a prescriber allows home testing, they must have procedures in place to reduce the risk of results being misunderstood or falsified. (Source: FDA, Questions and Answers on the iPLEDGE REMS)
What happens if the prescription is not picked up in time?
Previously, people who could become pregnant faced an additional waiting period if they did not obtain their isotretinoin prescription within 7 days of a negative pregnancy test. That extra waiting period has been removed.
They may now repeat the pregnancy test immediately. For someone who has not yet started treatment, the repeat test must be done in a medical setting. (Source: FDA, iPLEDGE Risk Evaluation and Mitigation Strategy)
Changes for people who cannot become pregnant
People who cannot become pregnant must still receive counseling when they enroll in iPLEDGE. Prescribers no longer have to record that counseling in the iPLEDGE system every month, although the information should continue to be reinforced throughout treatment.
The FDA also removed the 30-day prescription window for people who cannot become pregnant. If a prescription is not picked up, pharmacies must cancel the unused authorization in the REMS system and return the medication to stock. (Source: FDA, iPLEDGE Risk Evaluation and Mitigation Strategy)
Who needs to enroll or train again?
Existing patients, prescribers, and pharmacy representatives do not need to re-enroll or complete additional certification because of these changes.
Prescribers and pharmacy representatives must still complete their required annual recertification, and pharmacy staff must continue annual training. The FDA says the updates are intended to reduce administrative obstacles and improve access without removing the program’s pregnancy safeguards. (Source: FDA, iPLEDGE Risk Evaluation and Mitigation Strategy)
For questions about isotretinoin or how the requirements apply to you, speak with your doctor or dermatologist. This article is for general information and is not a substitute for medical advice.
Sources
- U.S. Food and Drug Administration. iPLEDGE Risk Evaluation and Mitigation Strategy (REMS). Updated June 16, 2026. Accessed November 16, 2026.
- U.S. Food and Drug Administration. Questions and Answers on the iPLEDGE REMS. Accessed November 16, 2026.
- U.S. Food and Drug Administration. Isotretinoin Capsule Information. Accessed November 16, 2026.